AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36331539 — intervention group
Group type: EXPERIMENTAL
Intervention: FREEDoM app-based mHealth intervention
Number of subjects: 11
Study 36331547 — intervention group
Group type: EXPERIMENTAL
Intervention: Technology-based obesity prevention interventions
Number of subjects: 7
Study 36331674 — intervention group
Group type: EXPERIMENTAL
Intervention: Orally-administered bendamustine hydrochloride, dosages ranging from 175 to 840 mg/m2, administered once daily for 7, 14, and 21 days every 3 weeks as one cycle.
Number of subjects: 0
Study 36331676 — intervention group
Group type: EXPERIMENTAL
Intervention: CA102N (0.72 mg/kg Nim equivalent)
Number of subjects: 37
Study 36331676 — intervention group
Group type: EXPERIMENTAL
Intervention: CA102N in combination with trifluridine-tipiracil
Number of subjects: 37
Study 36331681 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line cryoballoon ablation (CBA)
Number of subjects: 1394
Study 36331681 — intervention group
Group type: COMPARATOR
Intervention: CBA in antiarrhythmic drug (AAD)-refractory patients
Number of subjects: 1394
Study 36332004 — intervention group
Group type: EXPERIMENTAL
Intervention: NKTR-255 + CD19 CAR T cells
Number of subjects: 0
Study 36332004 — intervention group
Group type: COMPARATOR
Intervention: CD19 CAR T cells alone
Number of subjects: 0
Study 36332294 — intervention group
Group type: EXPERIMENTAL
Intervention: MRD positivity defined as ≥ 0.1% of leukemic bone marrow cells
Number of subjects: 189
Study 36332294 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated molecular risk classification
Number of subjects: 189
Study 36332294 — intervention group
Group type: EXPERIMENTAL
Intervention: MRD status
Number of subjects: 189
Study 36332294 — intervention group
Group type: EXPERIMENTAL
Intervention: Expression of CD25 by leukemic myeloblasts at diagnosis
Number of subjects: 189
Study 36332560 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial fluorescence imaging
Number of subjects: 80
Study 36332560 — intervention group
Group type: COMPARATOR
Intervention: Antibiotic therapy
Number of subjects: 80
Study 36332645 — intervention group
Group type: EXPERIMENTAL
Intervention: mOPV2
Number of subjects: 91
Study 36332645 — intervention group
Group type: EXPERIMENTAL
Intervention: nOPV2
Number of subjects: 91
Study 36332763 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 200 mg and 300 mg every 2 weeks
Number of subjects: 1902
Study 36332763 — intervention group
Group type: COMPARATOR
Intervention: Dupilumab
Number of subjects: 1902
Study 36332953 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral tenofovir/emtricitabine (TDF/FTC) with adherence self-management interventions (point-of-care urine drug-level assay, HIV self-testing, weekly text messaging)
Number of subjects: 120
Study 36332964 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6 antagonist therapy
Number of subjects: 0
Study 36333014 — intervention group
Group type: EXPERIMENTAL
Intervention: healthful plant-based diet index (hPDI)
Number of subjects: 11825
Study 36333014 — intervention group
Group type: COMPARATOR
Intervention: unhealthful plant-based diet index (uPDI)
Number of subjects: 11825
Study 36333128 — intervention group
Group type: EXPERIMENTAL
Intervention: FETO
Number of subjects: 18
Study 36333128 — intervention group
Group type: COMPARATOR
Intervention: non-FETO
Number of subjects: 18
Study 36333289 — intervention group
Group type: EXPERIMENTAL
Intervention: Next generation sequencing (NGS)
Number of subjects: 218
Study 36333463 — intervention group
Group type: EXPERIMENTAL
Intervention: Camidanlumab tesirine (Cami)
Number of subjects: 0
Study 36333464 — intervention group
Group type: EXPERIMENTAL
Intervention: Camidanlumab tesirine (Cami); specific dosage and duration not mentioned.
Number of subjects: 0
Study 36333533 — intervention group
Group type: EXPERIMENTAL
Intervention: Celtra Duo (CD)
Number of subjects: 10
Study 36333533 — intervention group
Group type: EXPERIMENTAL
Intervention: e.max CAD (EMA)
Number of subjects: 10
Study 36333533 — intervention group
Group type: EXPERIMENTAL
Intervention: UP.CAD (UP)
Number of subjects: 10
Study 36333533 — intervention group
Group type: EXPERIMENTAL
Intervention: Enamic (ENA)
Number of subjects: 10
Study 36333533 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyramic (HY)
Number of subjects: 10
Study 36333533 — intervention group
Group type: EXPERIMENTAL
Intervention: InCoris TZI (ZIR)
Number of subjects: 10
Study 36333533 — intervention group
Group type: EXPERIMENTAL
Intervention: Zirconia (ZIR)
Number of subjects: 10
Study 36333616 — intervention group
Group type: EXPERIMENTAL
Intervention: Worst Pruritus Numerical Rating Scale (WP-NRS)
Number of subjects: 882
Study 36333616 — intervention group
Group type: EXPERIMENTAL
Intervention: Atopic Dermatitis Symptom Scale (ADerm-SS) Skin Pain
Number of subjects: 882
Study 36333616 — intervention group
Group type: EXPERIMENTAL
Intervention: Atopic Dermatitis Symptom Scale (ADerm-SS) 7-Item Total Symptom Score (TSS-7)
Number of subjects: 882
Study 36333616 — intervention group
Group type: EXPERIMENTAL
Intervention: Atopic Dermatitis Impact Scale (ADerm-IS) Sleep
Number of subjects: 882
Study 36333616 — intervention group
Group type: EXPERIMENTAL
Intervention: Atopic Dermatitis Impact Scale (ADerm-IS) Daily Activities
Number of subjects: 882
Study 36333616 — intervention group
Group type: EXPERIMENTAL
Intervention: Atopic Dermatitis Impact Scale (ADerm-IS) Emotional State
Number of subjects: 882
Study 36333619 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT) sessions on a cycle ergometer for 4 weeks
Number of subjects: 11
Study 36333619 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT)
Number of subjects: 11
Study 36333619 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic model using five affected parameters
Number of subjects: 11
Study 36333618 — intervention group
Group type: EXPERIMENTAL
Intervention: Spesolimab 600-mg loading dose followed by 300-mg maintenance dose every 4 weeks
Number of subjects: 4
Study 36333618 — intervention group
Group type: EXPERIMENTAL
Intervention: Spesolimab 600-mg loading dose followed by 300-mg maintenance dose every 12 weeks
Number of subjects: 4
Study 36333618 — intervention group
Group type: EXPERIMENTAL
Intervention: Spesolimab 300-mg loading dose followed by 150-mg maintenance dose every 12 weeks
Number of subjects: 4
Study 36333618 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 36333676 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose control treatment group
Number of subjects: 57
Study 36333676 — intervention group
Group type: EXPERIMENTAL
Intervention: Good collaterals
Number of subjects: 57
Study 36333676 — intervention group
Group type: COMPARATOR
Intervention: Poor collaterals
Number of subjects: 57
Study 36333682 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care CRP testing
Number of subjects: 8280
Study 36333718 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole genome sequencing (WGS) based diagnostics
Number of subjects: 200
Study 36333746 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-assisted early mobilization
Number of subjects: 30
Study 36333889 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal wearing of dentures
Number of subjects: 65
Study 36333889 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dentures)
Number of subjects: 65
Study 36334048 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose oral glutamine supplementation
Number of subjects: 9
Study 36334053 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm group (n=202)
Number of subjects: 374
Study 36334053 — intervention group
Group type: COMPARATOR
Intervention: Term group (n=172)
Number of subjects: 374
Study 36334053 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm infants
Number of subjects: 374
Study 36334053 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnancies complicated by threatened preterm labor or premature rupture of membranes
Number of subjects: 374
Study 36334163 — intervention group
Group type: EXPERIMENTAL
Intervention: Urgency NRS
Number of subjects: 1162
Study 36334236 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg
Number of subjects: 0
Study 36334236 — intervention group
Group type: COMPARATOR
Intervention: Ustekinumab 45/90 mg
Number of subjects: 0
Study 36334289 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-guided focused ultrasound (FUS) treatment targeting the hippocampus, frontal lobe, and parietal lobe, with 3 separate treatment sessions performed 2 weeks apart.
Number of subjects: 10
Study 36334289 — intervention group
Group type: COMPARATOR
Intervention: MRI-guided focused ultrasound (FUS) treatment
Number of subjects: 10
Study 36334312 — intervention group
Group type: EXPERIMENTAL
Intervention: KCCQ-12 assessment
Number of subjects: 1248
Study 36334312 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1248
Study 36335079 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy from the quitline
Number of subjects: 1944
Study 36335079 — intervention group
Group type: EXPERIMENTAL
Intervention: Any pharmacotherapy
Number of subjects: 1944
Study 36335079 — intervention group
Group type: COMPARATOR
Intervention: Nicotine replacement therapy receipt
Number of subjects: 1944
Study 36335079 — intervention group
Group type: COMPARATOR
Intervention: Nicotine replacement therapy use
Number of subjects: 1944
Study 36335079 — intervention group
Group type: COMPARATOR
Intervention: Quitting by insurance classifications
Number of subjects: 1944
Study 36335120 — intervention group
Group type: EXPERIMENTAL
Intervention: Abemaciclib plus pembrolizumab with anastrozole (cohort 1)
Number of subjects: 54
Study 36335120 — intervention group
Group type: EXPERIMENTAL
Intervention: Abemaciclib plus pembrolizumab without anastrozole (cohort 2)
Number of subjects: 54
Study 36335217 — intervention group
Group type: EXPERIMENTAL
Intervention: gedatolisib (180 mg QW) plus cisplatin
Number of subjects: 110
Study 36335217 — intervention group
Group type: EXPERIMENTAL
Intervention: gedatolisib (90-310 mg QW) plus docetaxel
Number of subjects: 110
Study 36335235 — intervention group
Group type: EXPERIMENTAL
Intervention: Septic shock (S group)
Number of subjects: 50
Study 36335366 — intervention group
Group type: EXPERIMENTAL
Intervention: Compulsive Exercise Test (CET)
Number of subjects: 572
Study 36335366 — intervention group
Group type: EXPERIMENTAL
Intervention: CET total score
Number of subjects: 572
Study 36335366 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index, weight loss attempts, physical fitness
Number of subjects: 572
Study 36335366 — intervention group
Group type: EXPERIMENTAL
Intervention: Introjected motivational regulation, HRQoL subscale parent relation and autonomy, exercise monitoring tool usage, weight loss attempts
Number of subjects: 572
Study 36335366 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity level
Number of subjects: 572
Study 36335479 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous acetazolamide (500 mg once daily)
Number of subjects: 519
Study 36335479 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 519
Study 36335531 — intervention group
Group type: EXPERIMENTAL
Intervention: Mavacamten
Number of subjects: 112
Study 36335531 — intervention group
Group type: COMPARATOR
Intervention: Placebo (cross-over to mavacamten from week 16 to week 32)
Number of subjects: 112
Study 36335531 — intervention group
Group type: COMPARATOR
Intervention: Mavacamten (cross-over group after 16 weeks)
Number of subjects: 112
Study 36335910 — intervention group
Group type: EXPERIMENTAL
Intervention: Elderly age (≥65 years)
Number of subjects: 330
Study 36335910 — intervention group
Group type: EXPERIMENTAL
Intervention: First medical contact (FMC) prior to attending the ED
Number of subjects: 330
Study 36335910 — intervention group
Group type: EXPERIMENTAL
Intervention: Women older than 65 years
Number of subjects: 330
Study 36335910 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical presentation in women and elderly patients
Number of subjects: 330
Study 36335915 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban (2.5 mg BID)
Number of subjects: 97
Study 36335915 — intervention group
Group type: COMPARATOR
Intervention: Vitamin K antagonist (VKA) phenprocoumon (INR 2.0 to 3.0)
Number of subjects: 97
Study 36336198 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine-learning-estimated structural progression score (s-score)
Number of subjects: 270
Study 36336198 — intervention group
Group type: EXPERIMENTAL
Intervention: Cartilage thickness loss
Number of subjects: 270
Study 36336468 — intervention group
Group type: EXPERIMENTAL
Intervention: Eribulin
Number of subjects: 76
Study 36336644 — intervention group
Group type: EXPERIMENTAL
Intervention: Management changes including acid suppression (30%) and thickened feedings (27%)
Number of subjects: 124
Study 36336644 — intervention group
Group type: EXPERIMENTAL
Intervention: Videofluoroscopic swallow study
Number of subjects: 124
Study 36336684 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic steatosis (measured by liver fat fraction using MRI)
Number of subjects: 100
Study 36336684 — intervention group
Group type: EXPERIMENTAL
Intervention: Degree of liver fibrosis (measured by ELF test)
Number of subjects: 100
Study 36336684 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin sensitivity measures (HOMA2S, Matsuda ISI, MinMod SI)
Number of subjects: 100
Study 36336750 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg twice daily
Number of subjects: 175
Study 36336899 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor treating fields (TTFields) with concurrent chemoradiation
Number of subjects: 0
Study 36336899 — intervention group
Group type: COMPARATOR
Intervention: Concurrent chemoradiation
Number of subjects: 0
Study 36336899 — intervention group
Group type: COMPARATOR
Intervention: Tumor treating fields (TTFields)
Number of subjects: 0
Study 36336905 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-guided walking program (at least 30 minutes or 6200 steps/day)
Number of subjects: 141
Study 36336905 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-guided walking program
Number of subjects: 141
Study 36337036 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary flow reserve (CFR) <2.0 (55.2% of patients)
Number of subjects: 67
Study 36337036 — intervention group
Group type: EXPERIMENTAL
Intervention: Low CFR
Number of subjects: 67
Study 36337437 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (CoQ10) 500 mg/day for 6 weeks
Number of subjects: 121
Study 36337437 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study 36337437 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (CoQ10) 500 mg/day
Number of subjects: 121
Study 36337437 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (CoQ10) and Placebo
Number of subjects: 121
Study 36337613 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistant starch type 4 (RS4) intake of 12 g/day for 12 weeks
Number of subjects: 0
Study 36337613 — intervention group
Group type: COMPARATOR
Intervention: Control group (specifics not provided)
Number of subjects: 0
Study 36337708 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-COVID condition group
Number of subjects: 428
Study 36337708 — intervention group
Group type: EXPERIMENTAL
Intervention: Montreal Cognitive Assessment, digit symbol test, phonetic verbal fluency
Number of subjects: 428
Study 36337708 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 428
Study 36337708 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-COVID condition individuals with cognitive complaints
Number of subjects: 428
Study 36337904 — intervention group
Group type: EXPERIMENTAL
Intervention: Long drug-eluting stents (DES)
Number of subjects: 103
Study 36337904 — intervention group
Group type: COMPARATOR
Intervention: Spot drug-eluting stents (DES)
Number of subjects: 103
Study 36338165 — intervention group
Group type: EXPERIMENTAL
Intervention: Cobalt chromium everolimus-eluting stent (EES)
Number of subjects: 7823
Study 36338165 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodegradable polymer biolimus-eluting stent
Number of subjects: 7823
Study 36338165 — intervention group
Group type: EXPERIMENTAL
Intervention: Platinum chromium-EES
Number of subjects: 7823
Study 36338165 — intervention group
Group type: EXPERIMENTAL
Intervention: Resolute zotarolimus-eluting stent
Number of subjects: 7823
Study 36338359 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole vessel plaque quantification
Number of subjects: 1013
Study 36338359 — intervention group
Group type: COMPARATOR
Intervention: % diameter stenosis and high-risk plaque characteristics (HRPC)
Number of subjects: 1013
Study 36338362 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-generation drug-eluting stent (DES)
Number of subjects: 5498
Study 36338362 — intervention group
Group type: COMPARATOR
Intervention: First-generation drug-eluting stent (DES)
Number of subjects: 5498
Study 36338374 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple crossover alone
Number of subjects: 2194
Study 36338374 — intervention group
Group type: COMPARATOR
Intervention: SB-opening procedure
Number of subjects: 2194
Study 36338374 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple crossover alone (LM subgroup)
Number of subjects: 2194
Study 36338374 — intervention group
Group type: COMPARATOR
Intervention: SB-opening procedure (LM subgroup)
Number of subjects: 2194
Study 36338374 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple crossover alone (true bifurcation subgroup)
Number of subjects: 2194
Study 36338374 — intervention group
Group type: COMPARATOR
Intervention: SB-opening procedure (true bifurcation subgroup)
Number of subjects: 2194
Study 36338402 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter edge-to-edge repair (TEER) using a novel device for severe MR
Number of subjects: 23
Study 36338409 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial CCTA
Number of subjects: 830
Study 36338415 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual Inflammatory Risk (RIR) determined by high-sensitivity C-reactive protein (hsCRP) measurements
Number of subjects: 4562
Study 36338415 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent high RIR (hsCRP ≥2 mg/L)
Number of subjects: 4562
Study 36338481 — intervention group
Group type: EXPERIMENTAL
Intervention: 7% solution of xylitol
Number of subjects: 0
Study 36338481 — intervention group
Group type: COMPARATOR
Intervention: 7% solution of free sugars (glucose, fructose, sucrose)
Number of subjects: 0
Study 36338546 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined inhibition of DDK and WEE1
Number of subjects: 0
Study 36338546 — intervention group
Group type: COMPARATOR
Intervention: DDK inhibitor
Number of subjects: 0
Study 36338546 — intervention group
Group type: COMPARATOR
Intervention: WEE1 inhibitor
Number of subjects: 0
Study 36338546 — intervention group
Group type: COMPARATOR
Intervention: Inhibition of CDK1 or microtubule polymerization
Number of subjects: 0
Study 36338743 — intervention group
Group type: EXPERIMENTAL
Intervention: Third dose (booster) of COVID-19 mRNA vaccination (Pfizer-BioNTech or Moderna)
Number of subjects: 320
Study 36338743 — intervention group
Group type: COMPARATOR
Intervention: First two doses of COVID-19 mRNA vaccination
Number of subjects: 320
Study 36339063 — intervention group
Group type: EXPERIMENTAL
Intervention: CT coronary angiography (CTCA) for quantitative plaque characterization
Number of subjects: 327
Study 36339117 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 1096
Study 36339117 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1096
Study 36339122 — intervention group
Group type: EXPERIMENTAL
Intervention: Cobalt-chromium everolimus-eluting stents (CoCr-EES)
Number of subjects: 6645
Study 36339122 — intervention group
Group type: EXPERIMENTAL
Intervention: Resolute zotarolimus-eluting stents (Re-ZES)
Number of subjects: 6645
Study 36339122 — intervention group
Group type: EXPERIMENTAL
Intervention: Platinum-chromium EES (PtCr-EES)
Number of subjects: 6645
Study 36339122 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioresorbable polymer SES (BP-SES)
Number of subjects: 6645
Study 36339122 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrathin strut biodegradable-polymer sirolimus-eluting stents (UT-SES)
Number of subjects: 6645
Study 36339121 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel shellac plus vitamin E-based DCB
Number of subjects: 82
Study 36339121 — intervention group
Group type: COMPARATOR
Intervention: Reference iopromide-based DCB
Number of subjects: 82
Study 36339124 — intervention group
Group type: EXPERIMENTAL
Intervention: Women (FFR value)
Number of subjects: 655
Study 36339124 — intervention group
Group type: COMPARATOR
Intervention: Men (FFR value)
Number of subjects: 655
Study 36339124 — intervention group
Group type: EXPERIMENTAL
Intervention: Women (high-risk plaque characteristics)
Number of subjects: 655
Study 36339124 — intervention group
Group type: COMPARATOR
Intervention: Men (high-risk plaque characteristics)
Number of subjects: 655
Study 36339124 — intervention group
Group type: EXPERIMENTAL
Intervention: Women (myocardial mass)
Number of subjects: 655
Study 36339124 — intervention group
Group type: COMPARATOR
Intervention: Men (myocardial mass)
Number of subjects: 655
Study 36339126 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor plus aspirin (T+A)
Number of subjects: 405
Study 36339126 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone (A)
Number of subjects: 405
Study 36339126 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline HbA1c <6.5%
Number of subjects: 405
Study 36339126 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline HbA1c ≥6.5%
Number of subjects: 405
Study 36339158 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition focused social marketing campaigns
Number of subjects: 400
Study 36339158 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified fishing traps that allow immature fish to escape
Number of subjects: 400
Study 36339158 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 400
Study 36339175 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-COVID-19 infected persons
Number of subjects: 547
Study 36339175 — intervention group
Group type: COMPARATOR
Intervention: Normative population
Number of subjects: 547
Study 36339175 — intervention group
Group type: COMPARATOR
Intervention: Chronic pain patients after spinal surgery
Number of subjects: 547
Study 36339368 — intervention group
Group type: EXPERIMENTAL
Intervention: Cobalt-chromium everolimus-eluting stents (EES)
Number of subjects: 1450
Study 36339368 — intervention group
Group type: EXPERIMENTAL
Intervention: Platinum-chromium everolimus-eluting stents (EES)
Number of subjects: 1450